723 related articles for article (PubMed ID: 15877053)
1. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
2. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
3. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
4. Pharmacogenomics: will the regulators approve?
Hodgson J; Marshall A
Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002
[No Abstract] [Full Text] [Related]
5. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
6. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
7. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
8. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
9. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
[No Abstract] [Full Text] [Related]
10. FDA pharmacogenomics guidance sends clear message to industry.
Ratner M
Nat Rev Drug Discov; 2005 May; 4(5):359. PubMed ID: 15902767
[No Abstract] [Full Text] [Related]
11. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
12. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
13. FDA issues pharmacogenomics data submission guidance.
Expert Rev Mol Diagn; 2005 May; 5(3):275-7. PubMed ID: 15934806
[No Abstract] [Full Text] [Related]
14. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
15. FDA guidance on pharmacogenomics data submission.
Savage DR;
Nat Rev Drug Discov; 2003 Dec; 2(12):937-8. PubMed ID: 14756137
[No Abstract] [Full Text] [Related]
16. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
[TBL] [Abstract][Full Text] [Related]
17. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
18. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
19. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
20. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
